Abstract
Clinical prospective double blind study was carried out to investigate the effect of ascorbic acid on mental depression therapy and the possible therapeutic interaction with the pharmacotherapy of the disease. The study involves twenty two outpatients. The psychiatrist assessed diagnostic status according to diagnostic and statistical manual of mental disorders 4th edition (DSM-IV) and prescribes a suitable antidepressant drugs to the patients. Patients were assessed at baseline before medication started and after eight-week. The principal measure of the outcome was Hamilton Rating Scale for Depression (HAM-D 17-item). The mean decrease in HAM-D score from baseline was used as the main outcome measure of response of depression to treatment. The physical examination and clinical laboratory investigations including a complete urine analysis, biochemical, haematology analysis, and plasma ascorbic acid was measured, at baseline and after eight-week of receiving both ascorbic acid or placebo.
Highlights
Clinical prospective double blind study was carried out to investigate the effect of ascorbic acid on mental depression therapy and the possible therapeutic interaction with the pharmacotherapy of the disease
In group A, 8 patients were treated with paroxetine 20 mg, 2 patients were treated with fluoxetine 20 mg, 1 patient was treated with combination of olanzapine 10 mg and clomipramine 75 mg, 1 patient was treated with clomipramine 75 mg, and 1 patient was treated with fluvoxamine 20 mg
In group B, 5 patients were treated with paroxetine 20 mg, 1 patient was treated with combination of olanzapine 10 mg and fluoxetine 20 mg, 1 patient was treated with combination of quatipine 200 mg and clomipramine 75mg, and 2 patients were treated with clomipramine 75 mg
Summary
Mental Depression Drug Therapy in Presence of Ascorbic Acid: Clinical Study Clinical prospective double blind study was carried out to investigate the effect of ascorbic acid on mental depression therapy and the possible therapeutic interaction with the pharmacotherapy of the disease. The mean decrease in HAM-D score from baseline was used as the main outcome measure of response of depression to treatment.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
